ZA202404615B - Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer - Google Patents
Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancerInfo
- Publication number
- ZA202404615B ZA202404615B ZA2024/04615A ZA202404615A ZA202404615B ZA 202404615 B ZA202404615 B ZA 202404615B ZA 2024/04615 A ZA2024/04615 A ZA 2024/04615A ZA 202404615 A ZA202404615 A ZA 202404615A ZA 202404615 B ZA202404615 B ZA 202404615B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitor
- treating cancer
- methods
- dosing regimens
- cdk2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163285457P | 2021-12-02 | 2021-12-02 | |
| PCT/IB2022/061652 WO2023100134A1 (en) | 2021-12-02 | 2022-12-01 | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202404615B true ZA202404615B (en) | 2025-12-17 |
Family
ID=84462534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/04615A ZA202404615B (en) | 2021-12-02 | 2024-06-13 | Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| EP4604961A1 (en) * | 2022-10-18 | 2025-08-27 | Pfizer Inc. | Compounds for the treatment of cancer |
| EP4719405A1 (en) * | 2023-06-02 | 2026-04-08 | Pfizer Inc. | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer |
| WO2025202871A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
| WO2025202854A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| WO2026133192A1 (en) * | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| CN118286225A (zh) | 2018-04-26 | 2024-07-05 | 辉瑞公司 | 作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物 |
| CA3128155C (en) | 2019-01-31 | 2023-09-19 | Pfizer Inc. | 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2 |
-
2022
- 2022-12-01 EP EP22821653.7A patent/EP4440575A1/en active Pending
- 2022-12-01 MX MX2024006747A patent/MX2024006747A/es unknown
- 2022-12-01 KR KR1020247021935A patent/KR20240112932A/ko active Pending
- 2022-12-01 IL IL312980A patent/IL312980A/en unknown
- 2022-12-01 US US18/715,085 patent/US20250041277A1/en active Pending
- 2022-12-01 JP JP2024532155A patent/JP2024544625A/ja active Pending
- 2022-12-01 AU AU2022402512A patent/AU2022402512A1/en not_active Abandoned
- 2022-12-01 CA CA3241001A patent/CA3241001A1/en active Pending
- 2022-12-01 WO PCT/IB2022/061652 patent/WO2023100134A1/en not_active Ceased
- 2022-12-01 CN CN202280090883.2A patent/CN118647379A/zh active Pending
- 2022-12-02 TW TW111146439A patent/TWI873485B/zh active
-
2024
- 2024-06-13 ZA ZA2024/04615A patent/ZA202404615B/en unknown
-
2026
- 2026-02-20 AU AU2026201311A patent/AU2026201311A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026201311A1 (en) | 2026-03-12 |
| IL312980A (en) | 2024-07-01 |
| MX2024006747A (es) | 2024-06-19 |
| US20250041277A1 (en) | 2025-02-06 |
| KR20240112932A (ko) | 2024-07-19 |
| TW202332431A (zh) | 2023-08-16 |
| TWI873485B (zh) | 2025-02-21 |
| WO2023100134A1 (en) | 2023-06-08 |
| CA3241001A1 (en) | 2023-06-08 |
| CN118647379A (zh) | 2024-09-13 |
| EP4440575A1 (en) | 2024-10-09 |
| AU2022402512A1 (en) | 2024-06-20 |
| JP2024544625A (ja) | 2024-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024006747A (es) | Metodos y regimenes de dosificacion que comprenden un inhibidor de cinasa 2 dependiente de ciclina (cdk2) y un inhibidor de cinasa 4 dependiente de ciclina (cdk4) para el tratamiento de cancer. | |
| PH12019502379A1 (en) | Pd-1/pd-l1 inhibitors | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| CR20200347A (es) | Inhibidores pd-1/pd-l1 | |
| MX393974B (es) | Terapia de combinacion para tratamiento de cancer. | |
| MX2020006963A (es) | Composiciones y metodos para tratar anemia. | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| MX385778B (es) | Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario. | |
| AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
| BR112022011998A2 (pt) | Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas | |
| EA201792650A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
| PH12014500869A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| MX2010005095A (es) | Moduladores novedosos de puntos de verificación del ciclo celular y su uso en combinacion con inhibidores de cinasa de puntos de verificacion. | |
| MX2022006366A (es) | Terapia de combinacion que implica compuestos de diarilo macrociclico. | |
| MX2021013631A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de t1dm e insulitis. | |
| MX2023007850A (es) | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). | |
| MX2019013862A (es) | Terapia de combinacion. | |
| ES2723827T3 (es) | Terapia de combinación de fármacos para el tratamiento de tumores sólidos | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| PH12022552347A1 (en) | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors | |
| MX2024013787A (es) | Inhibidores de menina-mll para el tratamiento de cáncer. | |
| ZA201800787B (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| MX2024012392A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. |